Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- New trial
Multiple solid tumors
Phase I trial of ulixertinib, an ERK1/2 inhibitor, with palbociclib, a CDK4/6 inhibitor.
This phase I open-label study by UNC Lineberger evaluates safety, MTD, and RP2D of ulixertinib plus palbociclib in patients with advanced solid tumors and refractory melanoma. The trial includes dose escalation and…
NCT03454035 - New trial
Multiple solid tumors
Phase 1 PF-08046037 TLR7 agonist ADC study in advanced malignancies.
Pfizer is evaluating PF-08046037 as monotherapy or with sasanlimab in an open-label trial enrolling patients with advanced NSCLC, HNSCC, melanoma, or PDAC. The study will assess safety, dosing, and initial efficacy…
NCT06974734 - New trial
Multiple solid tumors
Phase I ATLCAR.CD30.CCR4: CAR‑T cells targeting CD30 with CCR4‑mediated tumor homing
This study evaluates ATLCAR.CD30.CCR4 therapy—administered alone or with ATLCAR.CD30 cells—to determine safe dosing in patients with relapsed/refractory CD30+ lymphomas (including Hodgkin, Grey Zone, and T‑cell…
NCT03602157 - New trial
Multiple solid tumors
Phase 2 MDX-1105 PD-L1 mAb trial
Investigators at UPMC are assessing whether discontinuing PD-L1 inhibitor therapy after one year maintains disease stability in patients with advanced solid tumors. The randomized study includes multiple tumor types…
NCT04157985 - New trial
Multiple solid tumors
Phase I IDOV-Immune oncolytic virus trial in advanced solid tumors
This Phase I, open-label, multi-center study by ViroMissile, Inc. is evaluating IDOV-Immune, an oncolytic vaccinia virus therapy, administered as a single IV infusion in adults with advanced, treatment-resistant…
NCT06910657 - New trial
Multiple solid tumors
Phase 1/2 study of YH42946, EGFR and HER2 (+ex20) inhibitor small molecule
YH42946-101 is a first-in-human, open-label, multicenter study from Yuhan Corporation evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity via dose escalation to determine the maximum tolerated…
NCT06616766 - New trial
Multiple solid tumors
Phase III pCSI Proton Beam Therapy for Precise CNS Leptomeningeal Targeting
This Phase III randomized trial by NRG Oncology compares proton craniospinal irradiation with standard involved-field radiotherapy for patients with leptomeningeal metastasis from breast or non-small cell lung…
NCT06500481 - Trial result
Multiple solid tumors
Entrectinib Nets 69% ORR in Children with ROS1-Fusion Solid & CNS Tumors
Entrectinib, an oral TRK/ROS1 inhibitor, was pooled across the phase 1–2 STARTRK-NG (NCT02650401), TAPISTRY (NCT04589845), and STARTRK-2 (NCT02568267) trials. Across 26 ROS1-fusion patients (<18 y) there was a 69%…
NCT02650401 - Trial result
Multiple solid tumors
Pembrolizumab Clears Tumors in 58% of MSI-H Cancers, 47% Alive at 10 Years
PD-1 inhibitors, like pembrolizumab, showed strong efficacy in dMMR/MSI-H cancers. KEYNOTE-016 (NCT01876511), a multicenter phase 2 trial, gave pembrolizumab 2 mg/kg Q2W to 88 adults with heavily pre-treated…
NCT01876511 - Trial result
Multiple solid tumors
GFH375 KRAS-G12D Inhibitor Delivers 38% ORR — 52% in Pancreatic Cancer
GFH375 is an oral inhibitor that locks mutant KRAS G12D in both its GDP- and GTP-bound states. In a first-in-human Phase I/II study in China (NCT06500676), 32 heavily pre-treated patients with KRAS G12D-mutant solid…
NCT06500676 - Trial result
Multiple solid tumors
ctDNA Drop ≥50% by Cycle 3 Flags Long-Term Benefit from Atezolizumab Across Solid Tumors
Cell-free DNA (cfDNA) refers to fragments of DNA released into the bloodstream from dying cells, including circulating tumor DNA (ctDNA) from cancer cells. In the MyPathway pan-tumor cohort (phase II, n = 153;…
NCT02091141 - Trial result
Multiple solid tumors
Pralsetinib RET Inhibitor Shrinks Diverse Tumors (46% ORR, 11-mo DoR)
Pralsetinib is a tyrosine kinase inhibitor designed to target cancer-driving RET fusions and mutations. In the Phase 2 ARROW basket trial (n = 29; 11 histologies, NCT03037385), adults with pre-treated, RET…
NCT03037385 - New trial
Multiple solid tumors
Phase 1 Study of XB628 Targeting NKG2A and PD-L1 in Advanced Solid Tumors
Exelixis is conducting a first-in-human, open-label, dose-escalation trial of XB628—a bispecific antibody that engages NK cells by targeting NKG2A and PD-L1—in patients with recurrent advanced or metastatic solid tumors.
NCT06952010 - New trial
Multiple solid tumors
Phase 1 FIH Study of ABBV-324 (Undisclosed ADC) in HCC and Squamous NSCLC
AbbVie is evaluating ABBV-324—an investigational antibody–drug conjugate with an undisclosed target—in patients with advanced hepatocellular carcinoma and squamous-cell non–small cell lung cancer through dose…
NCT06858813 - New trial
Multiple solid tumors
Phase I/IIa FAP-Targeted Alpha-Particle Therapy in FAP-Positive Solid Tumors
Perspective Therapeutics is evaluating both imaging and therapeutic peptide-based radiopharmaceuticals ([203Pb]Pb-PSV359 for imaging and [212Pb]Pb-PSV359 for alpha-particle treatment) across dose escalation and…
NCT06710756 - New trial
Multiple solid tumors
Pilot PET Imaging Study of [89Zr]DFO-starPEG for EPR in Solid Tumors
This first-in-human pilot study assesses the novel PET radiotracer [89Zr]DFO-starPEG—designed to visualize the enhanced permeability and retention (EPR) effect—for its ability to capture whole-body tracer uptake at…
NCT06894745 - New trial
Multiple solid tumors
ASP-1929 Photoimmunotherapy with Anti-PD1 in Advanced EGFR-Expressing Squamous Cancers
Rakuten Medical is conducting an open-label study evaluating ASP-1929—a cetuximab-based, EGFR-targeted photoactivatable agent—in combination with PD-1 inhibitors (pembrolizumab or cemiplimab) across…
NCT04305795 - New trial
Multiple solid tumors
Phase II Trial of Optimal Margins in Brain Metastases Radiosurgery
UAB is evaluating differential planning target volume margins (0 mm vs 2 mm) in single isocenter radiosurgery for brain metastases ≤4 cm to optimize dosing based on tumor size.
NCT06857006 - New trial
Multiple solid tumors
Phase II Trial of VMAT CSI in Leptomeningeal Metastasis
NYU Langone Health is evaluating linac-based Volumetric Modulated Arc Therapy (VMAT) craniospinal irradiation (CSI) in solid tumor patients with leptomeningeal metastasis to improve central nervous system…
NCT06984523 - Trial result
Multiple solid tumors
Pembrolizumab (PD-1) neoadjuvant delivers 80% 3-yr EFS in dMMR/MSI-H tumors; ctDNA pinpoints relapse risk
Phase II NCT04082572 enrolled 35 patients with locally advanced dMMR/MSI-H solid tumors who received neoadjuvant pembrolizumab; at 3 years, event-free and overall survival reached 80% (95% CI 66-93) and 94% (86-100).…
NCT04082572 - Trial result
Multiple solid tumors
BMS-986504 (PRMT5-MTA inhibitor) posts 23% ORR and 10.5-mo responses in MTAP-deleted solid tumors
In the first-in-human Phase I/II CA240-0007 study (ASCO #3011), 152 heavily pre-treated patients with homozygous MTAP-deleted advanced cancers—most commonly PDAC (27%), NSCLC (22%), cholangiocarcinoma and…
- Trial result
Multiple solid tumors
DYP688 ADC Delivers Direct Gq/11 Inhibition with a 21.8% Response Rate in Metastatic Uveal Melanoma and other GNAQ/11 Mutant Melanomas
In the first-in-human Phase I dose-escalation study (NCT05415072, n = 66), DYP688 achieved a confirmed ORR of 21.8% (1 CR) in 55 evaluable patients with metastatic uveal or other GNAQ/11-mutant melanoma treated at ≥8…
NCT05415072 - Trial result
Multiple solid tumors
Larotrectinib, TRK Inhibitor, Achieves 77% Response in Treatment-Naïve (First-Line) TRK Fusion Cancers
In 101 patients across three trials including pediatric patients, larotrectinib, the TRK inhibitor, yielded a 77% overall response rate with median PFS of 61 months. Overall survival was not reached. Most…
- Trial result
Multiple solid tumors
Alectinib Shines on ALK Alterations in Advanced Solid Tumors including Children
In the TACKLE phase II trial in Japan, oral alectinib achieved a central-assessed ORR of 54.2% overall, with a median PFS of 24.9 months and OS of 38.8 months; responses were especially high in ALK fusions (76.5%…
- New trial
Multiple solid tumors
Phase 1/2a Trial of JAB-23E73 in Advanced KRAS-Altered Tumors
Jacobio is evaluating JAB-23E73—a small molecule KRAS inhibitor—in a multi-cohort study assessing safety, tolerability, pharmacokinetics, and preliminary antitumor activity in advanced solid tumors, including NSCLC,…
NCT06973564 - New trial
Multiple solid tumors
Phase 1 Trial of GEN1057 Targeting FAP alpha and DR4 in Advanced Solid Tumors
Genmab is conducting a first-in-human, open-label dose escalation study of GEN1057—a bispecific mAb targeting FAP alpha and DR4—to evaluate its safety and antitumor activity in patients with advanced or metastatic…
NCT06573294 - New trial
Multiple solid tumors
Augmented PET/CT Enhances Malignant Lesion Detection in Carcinoma
Washington University is evaluating AWSM-PET/CT—a technology designed to boost resolution and sensitivity—for improved detection of malignant lesions compared to standard FDG-PET/CT in carcinoma patients.
NCT05513027 - Trial result
Multiple solid tumors
Pembrolizumab Erases ctDNA in Median 2 Cycles, Boosting 3-Year EFS to 92 % in dMMR/MSI-H Tumors
Phase II neoadjuvant trial NCT04082572 tracked 35 locally advanced dMMR/MSI-H cancers for 3 years: overall EFS/OS were 80% / 94%, but patients who cleared ctDNA after pembrolizumab hit 3-year EFS 92% and OS 100%…
NCT04082572 - New trial
Multiple solid tumors
Phase 1a/1b Trial of LY3962673 in KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company is evaluating LY3962673—an oral KRAS (G12D) inhibitor—as a monotherapy and in combination with various chemotherapy agents in patients with advanced, unresectable solid tumors. The study…
NCT06586515 - New trial
Multiple solid tumors
Phase I/II Trial: GDC-7035 in KRAS G12D-Mutant Advanced Solid Tumors
Genentech, Inc. is conducting a first-in-human, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of GDC-7035—a KRAS (G12D) inhibitor—administered both as a single agent and in…
NCT06619587
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.